Abstract:Importance: The immunopathogenic mechanisms of dry eye disease (DED), one of the most common ophthalmic conditions, is incompletely understood. Data from this prospective, double-masked, randomized trial demonstrate that targeting interleukin 1 (IL-1) by topical application of an IL-1 antagonist is efficacious in significantly reducing DED-related patient symptoms and corneal epitheliopathy. Objective: To evaluate the safety and efficacy of treatment with the topical IL-1 receptor antagonist anakinra (Kineret; Amgen Inc) in patients having DED associated with meibomian gland dysfunction. Design and setting: Prospective phase 1/2, randomized, double-masked, vehicle-controlled clinical trial. Participants: Seventy-five patients with refractory DED. Interventions: Participants were randomized to receive treatment with topical anakinra, 2.5% (n = 30), anakinra, 5% (n = 15), or vehicle (1% carboxymethylcellulose) (n = 30) 3 times daily for 12 weeks. Main outcomes and measures: Primary outcomes were corneal fluorescein staining (CFS), complete bilateral CFS clearance, dry eye-related symptoms as measured by the Ocular Surface Disease Index, tear film breakup time, and meibomian gland secretion quality. Results: Topical anakinra was well tolerated compared with vehicle, with no reports of serious adverse reactions attributable to the therapy. After 12 weeks of therapy, participants treated with anakinra, 2.5%, achieved a 46% reduction in their mean CFS score (P = .12 compared with vehicle and P < .001 compared with baseline); participants treated with anakinra, 5%, achieved a 17% reduction in their mean CFS score (P = .88 compared with vehicle and P = .33 compared with baseline); and patients treated with vehicle achieved a 19% reduction in their mean CFS score (P = .11). Complete bilateral CFS clearance was noted in 8 of 28 patients (29%) treated with anakinra, 2.5%, vs in 2 of 29 patients (7%) treated with vehicle (P = .03). By week 12, treatment with anakinra, 2.5%, and treatment with anakinra, 5%, led to significant reductions in symptoms of 30% and 35%, respectively (P = .02 and P = .01, respectively, compared with vehicle); treatment with vehicle led to a 5% reduction in symptoms. Conclusions and relevance: Treatment with topical anakinra, 2.5%, for 12 weeks was safe and significantly reduced symptoms and corneal epitheliopathy in patients with DED. These data suggest that the use of an IL-1 antagonist may have a role as a novel therapeutic option for patients with DED. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00681109.

Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study

Protective Role of Hinokitiol Against H2O2-Induced Injury in Human Corneal Epithelium

Honokiol: an effective inhibitor of tumor necrosis factor-α-induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts

Effects of Antioxidant and Nitric Oxide on Chemokine Production in Tnf-Alpha-Stimulated Human Dermal Microvascular Endothelial Cells

Effects of Antioxidants and Nitric Oxide on TNF-α-induced Adhesion Molecule Expression and NF-κB Activation in Human Dermal Microvascular Endothelial Cells

Differential Effects of Low- and High-Dose Glucocorticoids on the Innate Immunity of Corneal Epithelium in Vitro

Quercetin inhibits hypertonicity-induced inflammatory injury in human corneal epithelial cells via the PTEN/PI3K/AKT pathway

Hinokitiol reduces matrix metalloproteinase expression by inhibiting Wnt/β-Catenin signaling in vitro and in vivo.

Inhibitory Effects of Honokiol on Lipopolysaccharide-Induced Cellular Responses and Signaling Events in Human Renal Mesangial Cells

17-Β-estradiol Inhibits Hyperosmolarity-Induced Proinflammatory Cytokine Elevation Via the P38 MAPK Pathway in Human Corneal Epithelial Cells

Calcitriol Inhibits ROS-NLRP3-IL-1β Signaling Axis Via Activation of Nrf2-antioxidant Signaling in Hyperosmotic Stress Stimulated Human Corneal Epithelial Cells

Imbalanced IL-37/TNF-α/CTSS signaling disrupts corneal epithelial barrier in a dry eye model in vitro

Honokiol: an Effective Inhibitor of High-Glucose-Induced Upregulation of Inflammatory Cytokine Production in Human Renal Mesangial Cells

Protective effects of honokiol against oxidative stress-induced apoptotic signaling in mouse podocytes treated with H2O2.

Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation

Therapeutic effect of Atractylenolide I on Aspergillus fumigatus keratitis by affecting MyD88/ NF-κB pathway and IL-1β, IL-10 expression

The effect of astaxanthin on inflammation in hyperosmolarity of experimental dry eye model in vitro and in vivo

Puerarin alleviates hyperosmotic stress-induced oxidative stress, inflammation, apoptosis and barrier damage of human corneal epithelial cells by targeting SIRT1/NLRP3 signaling

Protective effect of Tisochrysis lutea on dry eye syndrome via NF-κB inhibition

Ectoine protects corneal epithelial survival and barrier from hyperosmotic stress by promoting anti-inflammatory cytokine IL-37

Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial